We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Seegene

Seegene, Inc. is a developer of multiplex molecular technologies and multiplex clinical molecular diagnostics for inf... read more Featured Products: More products

Download Mobile App





Seegene Develops World’s First COVID-19 Mutant Identification Test

By LabMedica International staff writers
Posted on 02 Feb 2021
Print article
Image: Allplex™ 2019-nCoV Assay (Photo courtesy of Seegene, Inc.)
Image: Allplex™ 2019-nCoV Assay (Photo courtesy of Seegene, Inc.)
Seegene, Inc. (Seoul, Korea) has developed the world's first COVID-19 diagnostic variant test, capable of screening COVID-19 and identifying multiple mutant variations in a single reaction.

Seegene's new variant test, the Allplex SARS-CoV-2 Variants I Assay, can detect and differentiate virus variations, including those found to be more contagious and fatal. The new variant test not only detects COVID-19, but can also identify major genetic variations that seem to have originated from the UK, South Africa as well as other regions including Japan and Brazil. Furthermore, it can pre-screen a suspicious new variant, providing insight on additional variations, also a key feature of Seegene technology.

Seegene's new product integrates at least 10 of its proprietary technologies, including multiplex real-time PCR method of mTOCE, which is the cutting-edge technology that only the company can leverage. This innovative technology allows the test to detect a target specific spot where mutation occurs, enabling precise detection and differentiation of the coronavirus as well as its mutated versions with a single tube of reagent.

Another key feature using Seegene's unique technology is its endogenous internal control that can verify entire testing process including proper sample collection. By utilizing Seegene's big data auto-surveillance in silico system, the company is closely monitoring and analyzing worldwide database on COVID-19 and its variants, allowing it to quickly respond with product development.

The "new COVID-19 diagnostic variant test will significantly boost massive testing ability in its fight against the global-spread of mutant viruses when the time is key to controlling the pandemic," said an official from Seegene. According to the company official, Seegene plans "to supply its COVID-19 variant tests to global organizations and governments as its priority." The official added that the company will continue its work to "fulfill the duty as a leading global molecular diagnostics company by closely working with health authorities around the world."


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.